UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-32371
SINOVAC BIOTECH LTD.
No. 39 Shangdi Xi Rd, Haidian District
Beijing 100085, People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
SINOVAC BIOTECH LTD. |
| |
|
|
| |
By: |
/s/ Andrew Y. Yan |
| |
Name: |
Andrew Y. Yan |
| |
Title: |
Chairman of the Board |
Date: January 4, 2026
Exhibit Index
| Exhibit 99.1 |
|
Press Release – Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report |
| Exhibit 99.2 |
|
Press Release - SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement |
Exhibit 99.1
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025
Half-Year Report
BEIJING — Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC”
or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received
a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”),
stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form
6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025.
As previously disclosed, the Company received a delisting determination
letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq
Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel
will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has
been invited to present its views regarding this matter.
The Company is evaluating the Notification Letter and intends to present
its plan and views to the Nasdaq Hearings Panel at the scheduled hearing with the objective of maintaining its Nasdaq listing.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act
of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,”
“anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”
“potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based
upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties
and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which
may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information
regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange
Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information,
future events or otherwise, except as required under law.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical
company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development,
manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company’s diversified portfolio includes vaccines for influenza,
viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified
by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious
disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and
COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza
vaccine (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated
COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline
that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC
is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners.
Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development
and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for
future pandemics.
For more information, please see the Company’s website at www.sinovac.com.
Contacts
Investor and Media Contact
Sinovac Biotech Ltd.
Email: ir@sinovac.com
